Non-small cell lung cancer
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-NSCLC |
|---|---|
| Type | Disease |
| Aliases | NSCLCНДРЛНедрібноклітинний рак легені |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-EARLY-2024 SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 8046/3 |
|---|---|
| icd_o_3_topography | ["C34.9"] |
| icd_10 | C34 |
| who_classification | Non-small cell lung carcinoma — adenocarcinoma / squamous / large cell (WHO 5th 2021) |
Notes
archetype: biomarker_driven — molecular profiling the dominant branch point. Universal NGS panel (DNA + RNA fusion) recommended at metastatic diagnosis. Reflex PD-L1 IHC standard. Schema gaps absorbed by extra="allow" Base config: molecular_subtypes, stage_strata, pdl1_tps_strata. Pending unification with PROPOSAL §17/§18.
Used By
Actionability
BMA-ALK-EML4-V1-NSCLC- EML4-ALK variant 1 (E13;A20) is a stable fusion isoform with longer PFS on 2nd-gen ALK-TK...BMA-ALK-EML4-V3-NSCLC- EML4-ALK variant 3 is associated with shorter PFS on 2nd-gen ALK-TKIs (crizotinib/alectin...BMA-ALK-FUSION-NSCLC- ALK rearrangement in advanced NSCLC: alectinib (ALEX, Peters 2017) and lorlatinib (CROWN,...BMA-ALK-G1202R-NSCLC- ALK G1202R is a solvent-front mutation conferring resistance to 1st/2nd-gen ALK-TKIs (cri...BMA-ALK-L1196M-NSCLC- ALK L1196M is the gatekeeper mutation conferring resistance to crizotinib but retaining s...BMA-BRAF-CLASS3-NSCLC- Class 2 BRAF (e.g., K601E, L597, fusions) — RAS-independent, signal as dimers. Class 3 BR...BMA-BRAF-V600E-NSCLC- BRAF V600E in advanced NSCLC (≈1-2% of adenocarcinomas): dabrafenib + trametinib gives OR...BMA-DDR2-NSCLC-SQUAMOUS- DDR2 activating mutations are identified in ~2–4% of squamous cell carcinoma of the lung...BMA-EGFR-C797S-NSCLC- EGFR C797S is the principal acquired resistance mutation to osimertinib. Cis-configuratio...BMA-EGFR-EX19DEL-NSCLC- EGFR exon 19 deletion in advanced NSCLC: osimertinib 1L improves OS vs first-generation E...BMA-EGFR-EX20INS-NSCLC- EGFR exon 20 insertions (excluding A763_Y764insFQEA) are insensitive to classical EGFR-TK...BMA-EGFR-G719X-NSCLC- EGFR exon 18 G719X (G719A/C/S) is an "uncommon" sensitizing mutation (~3% of EGFR-mut NSC...BMA-EGFR-L858R-NSCLC- EGFR L858R in advanced NSCLC: osimertinib 1L is standard (FLAURA); L858R historically sho...BMA-EGFR-T790M-NSCLC- EGFR T790M is the dominant acquired-resistance mechanism after 1st/2nd-gen EGFR-TKI (gefi...BMA-ERBB4-NSCLC- ERBB4 (HER4) somatic activating mutations are identified in ~2–3% of NSCLC (mixed histolo...BMA-FGFR1-AMP-NSCLC-SQUAMOUS- FGFR1 amplification in squamous NSCLC (~15-20%). Multiple FGFR-TKI trials (lucitanib, AZD...BMA-KDR-NSCLC- KDR (VEGFR2) somatic activating mutations occur in ~2–3% of NSCLC across histologies. KDR...BMA-KRAS-A146T-NSCLC- KRAS A146T in NSCLC — rare; no approved targeted therapy.BMA-KRAS-G12C-NSCLC- KRAS G12C in advanced NSCLC (~13% of adenocarcinoma): sotorasib (CodeBreaK 100/200) and a...BMA-KRAS-G12D-NSCLC- KRAS G12D in NSCLC (~5%) — pan-KRAS / G12D-selective inhibitors in early trials. ICI-base...BMA-KRAS-G12V-NSCLC- KRAS G12V occurs in ~3–5% of NSCLC (less common than G12C ~13% and G12D ~5%). Unlike KRAS...BMA-KRAS-G13D-NSCLC- KRAS G13D in NSCLC — no approved KRASi; ICI-based therapy per usual algorithm.BMA-KRAS-Q61-NSCLC- KRAS Q61 in NSCLC — no approved targeted therapy.BMA-MET-AMP-NSCLC- High-level MET amplification in NSCLC: capmatinib activity in high-amp cohort of GEOMETRY...BMA-MET-EX14-NSCLC- MET exon 14 skipping in advanced NSCLC (~3-4% of adenocarcinoma): capmatinib (GEOMETRY mo...BMA-NRG1-FUSION-NSCLC- NRG1 fusions (~0.2% NSCLC; enriched in invasive mucinous adenocarcinoma, never-smokers) d...BMA-NTRK-FUSION-NSCLC- NTRK fusion in NSCLC is rare (~0.1-0.5%). Larotrectinib and entrectinib are FDA tumor-agn...BMA-PDL1-TPS-NSCLC- PD-L1 TPS informs pembrolizumab monotherapy selection in metastatic NSCLC; the TPS thresh...BMA-PIK3CA-HOTSPOT-NSCLC- PIK3CA mutations in ~5% of NSCLC squamous; no approved targeted therapy.BMA-RET-CCDC6-NSCLC- CCDC6-RET fusion is the second-most common RET fusion in NSCLC (~10-20%). Response to sel...BMA-RET-FUSION-NSCLC- RET fusion in advanced NSCLC (~1-2% of adenocarcinoma): selpercatinib (LIBRETTO-001 Drilo...BMA-RET-KIF5B-NSCLC- KIF5B-RET is the most common RET fusion in NSCLC (~70% of RET+ NSCLC). Treatment is ident...BMA-ROS1-CD74-NSCLC- CD74-ROS1 is the most common ROS1 fusion partner in NSCLC (~40-50% of ROS1+ cases) and as...BMA-ROS1-EZR-NSCLC- EZR-ROS1 (~15% of ROS1+ NSCLC) treated identically to other ROS1 fusions. Standard 1L: en...BMA-ROS1-FUSION-NSCLC- ROS1 rearrangement in advanced NSCLC: entrectinib (CNS-active) and crizotinib have establ...BMA-ROS1-G2032R-NSCLC- ROS1 G2032R is the dominant solvent-front resistance mutation after crizotinib or entrect...BMA-ROS1-SLC34A2-NSCLC- SLC34A2-ROS1 fusion (~10% of ROS1+ NSCLC) responds to standard ROS1-TKI therapy identical...BMA-TP53-MUT-NSCLC- TP53 mutations in NSCLC (~50%) — adverse prognostic; modulate ICI response (TP53+KRAS may...BMA-TP53-R175H-NSCLC- TP53 hotspot in NSCLC — adverse prognostic; modulates ICI response. Driven by usual NSCLC...BMA-TP53-R248Q-NSCLC- TP53 hotspot in NSCLC — adverse prognostic; modulates ICI response. Driven by usual NSCLC...- ... 2 more
Algorithms
ALGO-NSCLC-ADJUVANT- ALGO-NSCLC-ADJUVANTALGO-NSCLC-METASTATIC-1L- ALGO-NSCLC-METASTATIC-1LALGO-NSCLC-METASTATIC-2L- ALGO-NSCLC-METASTATIC-2LALGO-NSCLC-RESECTABLE-PERIOP- ALGO-NSCLC-RESECTABLE-PERIOP
Disease
DIS-SCLC- Small cell lung cancer
Handbook Chapters
HB-NSCLC-METASTATIC-1L- Metastatic NSCLC: driver-first treatment reasoning
Indication
IND-A1AT-DEFICIENCY-HCC-LUNG-PREVENTION-OBSERVATION- IND-A1AT-DEFICIENCY-HCC-LUNG-PREVENTION-OBSERVATIONIND-ENVIRONMENTAL-AIR-POLLUTION-LUNG-PREVENTION-MITIGATION- IND-ENVIRONMENTAL-AIR-POLLUTION-LUNG-PREVENTION-MITIGATIONIND-ENVIRONMENTAL-AIR-POLLUTION-LUNG-PREVENTION-OBSERVATION- IND-ENVIRONMENTAL-AIR-POLLUTION-LUNG-PREVENTION-OBSERVATIONIND-ENVIRONMENTAL-FRYING-EMISSIONS-PREVENTION-INTENSIFIED-SURVEILLANCE- IND-ENVIRONMENTAL-FRYING-EMISSIONS-PREVENTION-INTENSIFIED-SURVEILLANCEIND-ENVIRONMENTAL-FRYING-EMISSIONS-PREVENTION-OBSERVATION- IND-ENVIRONMENTAL-FRYING-EMISSIONS-PREVENTION-OBSERVATIONIND-ENVIRONMENTAL-SECONDHAND-SMOKE-LUNG-PREVENTION-ELIMINATION- IND-ENVIRONMENTAL-SECONDHAND-SMOKE-LUNG-PREVENTION-ELIMINATIONIND-ENVIRONMENTAL-SECONDHAND-SMOKE-LUNG-PREVENTION-OBSERVATION- IND-ENVIRONMENTAL-SECONDHAND-SMOKE-LUNG-PREVENTION-OBSERVATIONIND-IATROGENIC-BLEOMYCIN-LATE-PREVENTION-OBSERVATION- IND-IATROGENIC-BLEOMYCIN-LATE-PREVENTION-OBSERVATIONIND-IATROGENIC-BLEOMYCIN-LATE-PREVENTION-SURVEILLANCE- IND-IATROGENIC-BLEOMYCIN-LATE-PREVENTION-SURVEILLANCEIND-LIFESTYLE-TOBACCO-PREVENTION-CESSATION- IND-LIFESTYLE-TOBACCO-PREVENTION-CESSATIONIND-LIFESTYLE-TOBACCO-PREVENTION-OBSERVATION- IND-LIFESTYLE-TOBACCO-PREVENTION-OBSERVATIONIND-NSCLC-2L-BRAF-V600E-DAB-TRAM- IND-NSCLC-2L-BRAF-V600E-DAB-TRAMIND-NSCLC-2L-DATO-DXD- IND-NSCLC-2L-DATO-DXDIND-NSCLC-2L-DOCETAXEL-RAMUCIRUMAB- IND-NSCLC-2L-DOCETAXEL-RAMUCIRUMABIND-NSCLC-2L-EGFR-EX20INS-AMIVANTAMAB- IND-NSCLC-2L-EGFR-EX20INS-AMIVANTAMABIND-NSCLC-2L-EGFR-POST-OSI-AMI-LAZ- IND-NSCLC-2L-EGFR-POST-OSI-AMI-LAZIND-NSCLC-2L-HER2-MUT-T-DXD- IND-NSCLC-2L-HER2-MUT-T-DXDIND-NSCLC-2L-KRAS-G12C-ADAGRASIB- IND-NSCLC-2L-KRAS-G12C-ADAGRASIBIND-NSCLC-2L-KRAS-G12C-SOTORASIB- IND-NSCLC-2L-KRAS-G12C-SOTORASIBIND-NSCLC-2L-MET-AMP-CAPMATINIB- IND-NSCLC-2L-MET-AMP-CAPMATINIBIND-NSCLC-2L-MET-EX14-CAPMATINIB- IND-NSCLC-2L-MET-EX14-CAPMATINIBIND-NSCLC-2L-MET-EX14-TEPOTINIB- IND-NSCLC-2L-MET-EX14-TEPOTINIBIND-NSCLC-2L-NTRK-LAROTRECTINIB- IND-NSCLC-2L-NTRK-LAROTRECTINIBIND-NSCLC-2L-PD-L1-POST-IO-DOCETAXEL- IND-NSCLC-2L-PD-L1-POST-IO-DOCETAXELIND-NSCLC-2L-RET-FUSION-SELPERCATINIB- IND-NSCLC-2L-RET-FUSION-SELPERCATINIBIND-NSCLC-2L-ROS1-POST-CRIZ-ENTRECTINIB- IND-NSCLC-2L-ROS1-POST-CRIZ-ENTRECTINIBIND-NSCLC-2L-ROS1-REPOTRECTINIB- IND-NSCLC-2L-ROS1-REPOTRECTINIBIND-NSCLC-3L-DRIVER-BEYOND-2L- IND-NSCLC-3L-DRIVER-BEYOND-2LIND-NSCLC-3L-OSI-FAILURE-AMI- IND-NSCLC-3L-OSI-FAILURE-AMIIND-NSCLC-ADJUVANT-ATEZO-PDL1POS- IND-NSCLC-ADJUVANT-ATEZO-PDL1POSIND-NSCLC-ALK-1L-ENSARTINIB- IND-NSCLC-ALK-1L-ENSARTINIBIND-NSCLC-ALK-2L-LORLATINIB- IND-NSCLC-ALK-2L-LORLATINIBIND-NSCLC-ALK-MAINT-ALECTINIB- IND-NSCLC-ALK-MAINT-ALECTINIBIND-NSCLC-ALK-MET-1L- IND-NSCLC-ALK-MET-1LIND-NSCLC-BRAF-V600E-1L-DAB-TRAM- IND-NSCLC-BRAF-V600E-1L-DAB-TRAMIND-NSCLC-DRIVER-NEG-MET-1L-NIVO-IPI-CHEMO- IND-NSCLC-DRIVER-NEG-MET-1L-NIVO-IPI-CHEMOIND-NSCLC-EGFR-1L-AMI-LAZ- IND-NSCLC-EGFR-1L-AMI-LAZIND-NSCLC-EGFR-1L-OSI-CHEMO- IND-NSCLC-EGFR-1L-OSI-CHEMOIND-NSCLC-EGFR-MAINT-OSIMERTINIB- IND-NSCLC-EGFR-MAINT-OSIMERTINIBIND-NSCLC-EGFR-MUT-MET-1L- IND-NSCLC-EGFR-MUT-MET-1L- ... 38 more
Procedures
SUR-LUNG-LOBECTOMY- Anatomic lung lobectomy with mediastinal lymph node dissection
Questionnaires
QUEST-NSCLC-1L-STUB- Non-small cell lung cancer — first line
Red flag
RF-A1AT-DEFICIENCY-HCC-LUNG-PREVENTION- Alpha-1 antitrypsin (A1AT) deficiency, particularly homozygous PiZZ genotype (severe defi...RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK- Patient with active or incompletely controlled pre-existing autoimmune or inflammatory di...RF-ENVIRONMENTAL-AIR-POLLUTION-LUNG-PREVENTION- Chronic residential ambient air-pollution exposure with PM2.5 annual average >35 µg/m³ (W...RF-ENVIRONMENTAL-ARSENIC-WATER-PREVENTION- Chronic ingestion of arsenic-contaminated drinking water with inorganic arsenic >10 µg/L...RF-ENVIRONMENTAL-FRYING-EMISSIONS-PREVENTION- Sustained domestic exposure to indoor combustion emissions from high- temperature cooking...RF-ENVIRONMENTAL-SECONDHAND-SMOKE-LUNG-PREVENTION- Chronic involuntary exposure to environmental tobacco smoke (ETS, also "secondhand smoke"...RF-IATROGENIC-BLEOMYCIN-LATE-PREVENTION- Cancer survivor with history of bleomycin exposure — most commonly testicular germ-cell t...RF-IATROGENIC-PRIOR-RADIATION-PREVENTION- History of therapeutic radiation exposure ≥5 years ago to a body region — most commonly m...RF-LIFESTYLE-TOBACCO-CANCER-PREVENTION- Active tobacco smoking (current smoker OR cessation <15 years) OR smokeless tobacco use O...RF-NSCLC-ALK-FUSION-ACTIONABLE- ALK rearrangement / fusion (typically EML4-ALK) — ~5% of NSCLC adenocarcinoma; never-smok...RF-NSCLC-BRAF-V600E-ACTIONABLE- BRAF V600E mutation in NSCLC adenocarcinoma — ~1-2% prevalence. Dabrafenib + trametinib (...RF-NSCLC-BRAIN-METS-EMERGENCY- NSCLC with symptomatic brain metastases requiring emergency intervention: focal deficit,...RF-NSCLC-CORD-COMPRESSION- NSCLC with malignant epidural spinal cord compression (MESCC): new motor deficit, sensory...RF-NSCLC-EGFR-C797S-RESISTANCE- EGFR C797S — covalent-binding-site mutation that confers acquired resistance to osimertin...RF-NSCLC-EGFR-EX19DEL-ACTIONABLE- EGFR exon 19 deletion is the most common actionable EGFR-sensitizing mutation in NSCLC ad...RF-NSCLC-EGFR-EX20INS-ACTIONABLE- EGFR exon 20 insertion — heterogeneous in-frame insertions that sterically block 1st/2nd/...RF-NSCLC-EGFR-T790M-ACTIONABLE- Acquired EGFR T790M (gatekeeper) mutation at progression on 1st/2nd-gen EGFR-TKI (gefitin...RF-NSCLC-FRAILTY-AGE- Age ≥75 + ECOG ≥2 + significant comorbidity — concurrent CRT and platinum-doublet chemo p...RF-NSCLC-HER2-MUT-ACTIONABLE- HER2 (ERBB2) activating exon-20 mutation in NSCLC adenocarcinoma — ~2-3% prevalence; dist...RF-NSCLC-HER3-HIGH-PATRITUMAB-CANDIDATE- HER3 (ERBB3) high-expression / actionability surrogate in EGFR-mutant NSCLC progressing o...RF-NSCLC-HIGH-RISK-BIOLOGY- Actionable molecular driver detected (EGFR / ALK / ROS1 / KRAS G12C / BRAF V600E / MET ex...RF-NSCLC-INFECTION-SCREENING- Active TB OR latent TB conversion risk — ICI may trigger TB reactivation; pre-treatment I...RF-NSCLC-KRAS-G12C-ACTIONABLE- KRAS G12C mutation — ~13% of NSCLC adenocarcinoma; smoking-associated. Sotorasib (CodeBre...RF-NSCLC-MALIGNANT-EFFUSION- NSCLC with symptomatic malignant pleural / pericardial effusion: dyspnea at rest, hypoxia...RF-NSCLC-MET-AMP-ACTIONABLE- High-level MET amplification (MET/CEP7 ratio ≥4.0 OR mean GCN ≥10) in metastatic NSCLC —...RF-NSCLC-MET-EX14-ACTIONABLE- MET exon 14 skipping — ~3-4% of NSCLC adenocarcinoma; older / smoker enriched. Capmatinib...RF-NSCLC-NRG1-FUSION-ZENO-CANDIDATE- NRG1 (neuregulin-1) gene fusion in NSCLC — predominant in invasive mucinous adenocarcinom...RF-NSCLC-NTRK-FUSION-ACTIONABLE- NTRK1/2/3 gene fusion — pan-tumor actionable driver; <1% in NSCLC. Larotrectinib (NAVIGAT...RF-NSCLC-ORGAN-DYSFUNCTION- Pneumonitis history OR active interstitial lung disease (ILD) — limits ICI (pembrolizumab...RF-NSCLC-PDL1-50-PLUS- Metastatic NSCLC with PD-L1 tumor proportion score (TPS) ≥50% by 22C3 IHC, no actionable...RF-NSCLC-RET-FUSION-ACTIONABLE- RET fusion (KIF5B-RET, CCDC6-RET, others) — ~1-2% of NSCLC adenocarcinoma. Selpercatinib...RF-NSCLC-ROS1-FUSION-ACTIONABLE- ROS1 fusion (CD74-ROS1, EZR-ROS1, others) — ~1-2% of NSCLC adenocarcinoma; never-smoker e...RF-NSCLC-SVC-SYNDROME- NSCLC with superior vena cava syndrome: facial/upper-extremity edema, distended neck/ches...RF-NSCLC-TRANSFORMATION-PROGRESSION- Symptomatic CNS metastases OR superior vena cava (SVC) syndrome OR rapid radiographic pro...RF-NSCLC-TROP2-DATO-CANDIDATE- TROP2 expression in NSCLC — datopotamab deruxtecan (Dato-DXd) is a TROP2-directed deruxte...RF-OCC-ASBESTOS-MALIGNANCY-PREVENTION- Documented historical occupational exposure to asbestos fibres (chrysotile, amosite, croc...RF-OCC-DIESEL-EXHAUST-PREVENTION- Documented historical occupational exposure to diesel-engine exhaust (DEE) — typical high...RF-OCC-FIREFIGHTER-PREVENTION- Documented historical occupational exposure as a career firefighter (≥10 years in active...RF-OCC-IONIZING-RADIATION-PREVENTION- Documented historical occupational exposure to ionizing radiation — typical high-risk occ...RF-OCC-PAH-PREVENTION- Documented historical occupational exposure to polycyclic aromatic hydrocarbons (PAHs) —...- ... 6 more
Sources
SRC-ADAURA-WU-2020- Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung CancerSRC-ALEX-PETERS-2017- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerSRC-AURA3-MOK-2017- Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung CancerSRC-BR21-SHEPHERD-2005- Erlotinib in Previously Treated Non-Small-Cell Lung CancerSRC-BRF113928-PLANCHARD-2016- Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metasta...SRC-CASPIAN-PAZ-ARES-2019- Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of e...SRC-CHECKMATE-816-FORDE-2022- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerSRC-CHECKMATE-9LA-PAZ-ARES-2021- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients...SRC-CHRYSALIS-PARK-2021- Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on P...SRC-CODEBREAK200-JOHNSON-2023- Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G1...SRC-CROWN-SOLOMON-2021- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer (CROWN)SRC-DESTINYLUNG01-LI-2022- Trastuzumab Deruxtecan in Previously Treated HER2-Mutant Lung Cancer (DESTINY-Lung01)SRC-DESTINYLUNG02-GOTO-2023- Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer...SRC-EMPOWER-LUNG1-SEZER-2021- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer wi...SRC-ESMO-NSCLC-EARLY-2024- ESMO Clinical Practice Guideline on Early NSCLC + Stage IIISRC-ESMO-NSCLC-METASTATIC-2024- ESMO Clinical Practice Guideline on Metastatic Non-Small Cell Lung CancerSRC-FLAURA-2-PLANCHARD-2023- Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLCSRC-FLAURA-SORIA-2018- Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung CancerSRC-GEOMETRY-WOLF-2020- Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer (GEOMETRY m...SRC-IMPOWER-010-FELIP-2021- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cel...SRC-KEYNOTE-024-RECK-2016- Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerSRC-KEYNOTE-042-MOK-2019- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally adv...SRC-KEYNOTE-189-GANDHI-2018- Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerSRC-KEYNOTE-407-PAZ-ARES-2018- Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung CancerSRC-KEYNOTE-671-WAKELEE-2023- Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung CancerSRC-KRYSTAL1-JANNE-2022- Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation (KRYSTAL-1)SRC-LIBRETTO001-DRILON-2020- Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer (LIBRETTO-001)SRC-LUMELUNG1-RECK-2014- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treat...SRC-MARIPOSA-CHO-2024- Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLCSRC-MARIPOSA2-PASSARO-2024- Amivantamab plus Lazertinib in Osimertinib-Relapsed EGFR-Mutated Advanced Non-Small Cell...SRC-NAVIGATE-DRILON-2018- Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children (NAVIGATE...SRC-NCCN-NSCLC-2025- NCCN Clinical Practice Guidelines — Non-Small Cell Lung CancerSRC-NCIT- NCI Thesaurus — controlled cancer vocabularySRC-POSEIDON-JOHNSON-2023- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Th...SRC-REVEL-GARON-2014- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of sta...SRC-STARTRK2-DRILON-2020- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of th...SRC-TRIDENT1-DRILON-2024- Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer (TRIDENT-1)SRC-VISION-PAIK-2020- Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations (VISION)